Skip to content

Could Biocept (BIOC) spike once more?

Biocept (BIOC) currently trades at $0.39 and has fallen by 6.17% today. BIOC went down $0.2 from the previous closing price of $0.42. The high forecast for Biocept is $1.00 and the low is $0.15. The company’s market cap is $51.60 million with a 52 week high of $2.11 and a 52 week low of $0.21. BIOC has changed in price by -0.62 per share in the last 12 months. The company has recently sold 22.3M common shares at $0.46 per share, for gross proceeds of ~$10.3M, in a registered direct offering.


Biocept has a weak EPS of -1.22. This means the company lost $-1.22 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article. The probability of a spike is very unlikely for Biocept’s case.


About Biocept:
Biocept, Inc. is a commercial-stage cancer diagnostics company. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. Biocept serves patients and customers in the State of California.

Leave a Reply

%d bloggers like this: